Emergent BioSolutions anthrax vaccine gets boost - The Business Review (Albany):

ogarawo.wordpress.com
The Rockville-based company’s BioThrax has been granted a shelr life extension from the from its currenty three yearsto four. Under its contracft with the Department of Healtnh andHuman Services, the extension triggers a milestone payment of $30 milliojn for doses of the vaccine alreadg delivered to the Strategic National Stockpile. Emergent expects to recorde that payment as revenue this The shelf life extension also allowes Emergent to charge more for future doses of the vaccines delivered tothe government’s stockpile. That could raiswe the value of the contract to as muchas $405 million over the next several years.
Last year, the FDA approved a reducedx vaccination schedule tofive doses. Emergent continues researcb that could lead to a further reductio n in the number ofdosezs required, as well as the vaccine’s use to treat patientes after being exposed to Anthrax, not just as a pre-exposur e vaccine. Emergent has supplied the government’s stockpilde with 33 million dosezs of BioThraxso far. It is contracted to continue addinbg to stockpiles throughlate 2011. BioThra has been used to vaccinatd more than 2 million military personnelk since the government first started buying the vaccinein 1998. Emergen t stock (NYSE: EBS) was up 90 cents to $14.
6w per share in afternoon